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Abstract
Interleukin-21 (IL-21) is produced by activated T cells and it plays many diverse 
roles by regulating the functions of normal and abnormal cells. Its roles include 
regulation of proliferation, promotion of immune system and activation of apop-
tosis in B cells. IL-21R is a type-1 cytokine receptor and belongs to the IL-2R and 
IL-15R family. The signaling mechanisms of IL-21 in different cell types have been 
identified. However, we know less about the biological effects of IL-21 and its sig-
naling mechanisms in leukemia cells and monocytes. In this chapter, we will focus 
on IL-21’s biological effects and signaling pathways as well as discuss the potential 
implications and applications of IL-21 in leukemia cells. In these cells, IL-21 does 
not promote proliferation but enhances apoptosis and chemotaxis. Furthermore, 
IL-21 promotes differential expression of many cytokines including interleukins 
and chemokines. IL-21 activates both the Raf-ERK-MAPK and the Jak/STAT 
signaling pathways. These pathways mediate some of the effects of IL-21. Lastly, 
IL-21 also promotes activation of the STAT3 promoter and other transcriptional 
factors. These findings may be relevant to IL-21’s potential clinical implications and 
applications.
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1. Introduction
Interleukin-21 (IL-21) was first identified in 2000 through screening of a cDNA 
library from CD3+ human T cells [1]. Subsequently, the investigators identified a 
specific clone as containing pro-proliferative effects that was sensitive to neutraliza-
tion by the soluble IL-21R. Later investigators characterized this clone as a factor, 
which was subsequently renamed IL-21 [2]. The sequence of this new cytokine 
gene has an open reading frame that encodes for a 163 amino acid peptide, later 
confirmed as IL-21. Matured IL-21 is 15 kDa and it has four helix bundle cytokine 
domains and two pairs of cysteine residues showing significant homology to IL-2, 
IL-4, IL-15 and GM-CSF [2–4]. Based on these structural characteristics, [1] IL-21 
was placed in the IL-2 family. The IL-21 gene is located at chromosome 4q26–27 [1] 
and found to be approximately 180 kb from the IL-2 gene. In contrast, the human 
IL-15 gene is located on chromosome 4q31. Clearly, there is some commonality 
regarding the organization, gene structure, and location of these cytokines [1]. 
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Human IL-21 has 62% homology with murine IL-21 in addition to their two pairs 
of cysteine residues and well conserved WSEWS motif [5] even though the murine 
IL-21 gene is located on chromosome 3 [1].
Initial report indicated that IL-21 is produced exclusively by CD4+ T cells during 
their response to stimulation by anti-CD3 and anti-CD8 antibodies [6]. However, 
other cell types are known to produce IL-21 [2–5]. IL-21 has effects on many cell 
types including human leukemia cells and human monocytes [2–7]. The IL-21 
receptor (IL-21R) is expressed on both CD4+ and CD8+ T cells in which IL-21 
stimulates proliferation [1]. In addition, IL-21 promotes allogeneic-specific prolif-
eration of lymph node T cells, enhances cytolytic activity, induces IFN-γ production 
in T cells [2, 3] and enhances clonal expression of antigen-activated T cells [5, 6]. 
IL-21 also enhances naïve OT-1 cell response, enhances the affinity of the antigen-
specific CD8+ T cells, and regulates the functions of both T cells and B-lymphocytes 
[1, 6, 7]. It also plays important roles in B cell proliferation, differentiation and 
class switching [8]. IL-21 causes induction of apoptosis of resting primary B cells 
via downregulation of anti-apoptotic factors, Bcl-2 and Bcl-xL [9] an effect which 
differentiates IL-21 from other members of the IL-21 family known to promote 
proliferative and survival [2, 3, 7, 8].
In B-chronic lymphocytic leukemia cells (B-CLL) IL-21 enhances production 
of granzyme B, which mediates B-CCL apoptosis when these cells were co-treated 
with IL-21 and CpG oligodeoxynucleotide [9]. Thus, IL-21 has anti-proliferative 
effects on B lymphoma cell line [3, 10, 11] suggesting that IL-21 has potential 
anti-tumor activity against B-cell malignancies. IL-21 enhances transcription of 
genes that encode IL-21R, and IL-18R, all of which are involved in innate immunity 
[10–13]. IL-21 expression is Ca2+-dependent and that the IL-21 gene has three NFAT 
binding sites, which may be involved in regulation of the IL-21 gene promoter 
function by calcium ionophore [14]. In contrast to its known anti-proliferative 
effects [9, 10, 12, 13], IL-21 promotes growth, survival and induces DNA synthesis 
in human myeloma cell lines via Jak1/STAT2/3 mechanism [12]. In B cells, co-stim-
ulation by IL-21 leads to three effects: growth arrest, apoptosis or growth [12–16]. 
Furthermore, IL-21 promotes maturation of NK cells [14], enhances differentiation 
of NK cells via co-stimulation with either IL-2, or IL-15 or IL-18 and regulates the 
functions of many different cell types [17–20].
IL-21 receptor (IL-21R) was first discovered in 2000 [1, 2] by investigators who 
identified a clone structure from the human chromosome 16p11 that led to their 
discovery of a protein of 538 amino acids [9]. This protein of 60 kDa was later iden-
tified as the type 1 receptor with about 62% homology to the IL-4 receptor (39 kDa) 
whose gene is located on chromosome 16 [1, 16]. The IL-21R has two subunits, alpha 
and gamma and it is expressed in B cells, T cells, dendritic cells, NK cells, myeloma 
cell lines, lymphoma cell lines (IM-9, NK-92 and Jarkat cells), and lymphoid tissues 
including spleen and thymus in both CD4+ and CD8+ T cells [17, 18]. IL-21R is 
upregulated upon T cell receptor activation [17, 18]. IL-21R is also expressed and 
upregulated in epidermis of systemic sclerosis patients [18]. IL-21R has two pairs of 
conserved cysteine residues in its extracellular domain and a WSXWS motif proxi-
mal to its transmembrane domain. In addition, it has two Box 1 and 2 motifs, which 
serve as docking sites for cytoplasmic Jak kinases involved in transducing cellular sig-
naling from the IL-21R [21–25]. The γ-chain of IL-21R is an essential component of 
the IL-2 family of receptors that is critical for signaling as anti-γc antibodies blocked 
B cell proliferation induced by IL-21 and CD40, indicating that the gamma chain is 
involved in IL-21R signaling mechanisms [25, 26]. Furthermore, the Jak inhibitor 
WH-P131 blocked IL-21-induced proliferation of BaF3 cells via IL-21R confirming 
a role for Jak3 in IL-21R signaling. In addition, inhibition of the IL-21γc subunit by 
monoclonal antibody blocked IL-21-induced activation of Jak1, Jak3, and STAT1, 
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STAT2, STAT3 and STAT5 thus further supporting a critical role for IL-21 γc subunit 
in IL-21 signaling [26].
IL-21R associates with BCL-6 translocation in B cell lymphomas and expression 
of IL-21R is upregulated by CD40 leading to transduction of pro-apoptotic signals 
[27, 28]. In addition, IL-21R plays important roles in immunoglobulin produc-
tion and decreased in IL-21R expression is associated with decline in normal 
antibody production [28]. Furthermore, there is a decrease in IL-21R expression 
on B-lymphocytes in patients with systemic lupus erythromatosis (SLE) [29]. 
IL-21 synergizes with IL-15 to induce expansion of NK cells [1] and synergizes 
with IL-15 and IL-18 to upregulate IFNγ mRNA synthesis and production in NK 
and T cells. IL-21 also synergizes with IL-15 to promote proliferation of memory 
and naïve CD8+ [18], Furthermore, IL-21 has positive effect on tumor regression 
in B16 melanoma cells [24] as well as synergizes with IL-15 to delay CD11b bone 
marrow cell apoptosis [30]. In addition, IL-21 augments proliferation of IL-6-
dependent human myeloma cells expressing IL-21R and synergizes with TNF to 
enhance myeloma cell mitogenesis [3, 13]. These synergistic effects of IL-21 led to 
consideration of IL-21 as a potential therapeutic agent for many cell malignancies 
[30]. In contrast to its synergetic effects, IL-21 antagonizes IL-4’s ability to induce 
isotype switching in B cells from IgM to IgG and inhibits IFN-γ production by Th1 
cells an [31, 32].
In BAB/C mice undergoing immunization, IL-21 caused reduction in antigen-
induced eosinophil recruitment into the airway of the mice without affecting 
antigen-induced lymphocyte and macrophage recruitment [30]. However, 
another study [33] showed that IL-21 causes a decrease in antiovabumin IgE and 
IgG production, implying that IL-21 has anti-inflammatory effects in asthmatic 
patients and could serve as a potential therapy against asthma. The role of IL-21 in 
Crohn’s disease (CD) has been reported [34]. Since Steven Rosenberg and his team 
[35] reported that IL-2 has anti-tumor in cancer patients, there has been extensive 
interest on whether members of IL-2 family of cytokines could generate similar 
effects. Subsequently, there are many reported that IL-21 alone or in combination 
with other cytokines produces anti-growth effect in various animal cancer models 
and on a variety of solid tumors including tumors without IL-21R [11, 36]. IL-21 
is essential for IFN-γ induced expression of CXC chemokines, known to inhibit 
tumor angiogenesis. In addition, IL-21 induces tumor rejection by specific CTL 
and IFN-γ-dependent CXC chemokines in synergistic manner [37]. This anti-
tumor effect of IL-21 is independent of the systemic cytokine release by known 
inflammatory mediators like IFN-y, IL-4, IL-10 and IL-12 [38]. Either alone or 
in combination with IL-23, IL-21 exhibits strong anti-tumor and anti-metastasis 
effects in kidney renal cell carcinoma in BALB/C mice and in human esophageal 
carcinoma tumors [39, 40]. Similarly, combination treatment with IL-15 and 
IL-21 promoted nearly 100% rejection of head and neck squamous cell carcinoma 
(HNSCC) in 30% of the experimental animals [41, 42], indicating potential role 
of IL-21 and IL-15 in minimizing transfection of animals with HNSCC [41, 42]. 
Similar reports in metastatic lymphoma animal models have indicate that IL-21 
can act with other cytokines in combination therapy in the treatment of metastatic 
lymphoma tumors [43]. IL-21 enhances the synthesis of MIP-3α, a T cell chemoat-
tractant and induce chemotaxis in intestinal epithelial cells (HT-29), indicating 
that IL-21 enhances immune cell response and could serve as an effective addition 
to cancer immunotherapy [43–45].
Our rationale for examining IL-21 effects in human myeloid monocytic leuke-
mia cells and monocytes was based on the observations that IL-21 plays relevant 
roles in many types of cancer including solid tumors and lymphoma [36–43, 45]. 
However, little is known about the biologic effects of IL-21 in leukemia cells. In 
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addition, while the signaling pathways of IL-21 in many cell types are known, not 
much is known about the signaling pathway utilized by IL-21 in leukemia cells and 
monocytes. Furthermore, knowledge on potential cytokine induction ability of 
IL-21 in leukemia cells and monocytes was lacking. Our earlier preliminary report 
indicates that STAT3, Smad1, Smad2, and Smad3 are regulated by IL-21 in U937 
leukemia cells [46]. Additionally, IL-21 activates Jak/STAT and MAPK pathways in 
different cell types [47]. Therefore, the main purpose of our study was to determine 
the biological effects of IL-21 in human U937 leukemia and monocytes and to gain 
more insight into whether the Jak/STAT and MAPK-signaling pathways mediate 
IL-21’s specific biologic effects in these cells.
2. Materials and methods
U937 myeloid monocytic leukemia cells were obtained from ATCC and cultured 
in RPMI-1640 media containing L-glutamine and supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Atlanta Biological. GA) in the presence of 
5 U/ml penicillin +50 U/ml of streptomycin (Invitrogen, CA). The cultures were 
maintained in 5% CO2 at 37°C and 100% humidity. HeLa/STAT3-luc cells were 
created by co0transfection of pSTAT3-luc and pHygromycin into human cervical 
epithelial HeLa cells. These cells were maintained in the same culture in the pres-
ence of 100 μg/ml of hygromycin B (Roche, NJ) [7].
2.1 Monocyte isolation
Human PBMC were isolated from anonymous health individuals (NY Blood 
Center, Long Island, NY) by Ficoll gradient centrifugation at 400 × g for40 minutes 
at 20°C followed by Percoll gradient (GR Health Care, Piscataway, NJ) [7]. The 
mononuclear cells were recovered in RPMI media supplemented with 10% FBS, 
100 μg of streptomycin per ml and 100 U of penicillin per ml. The white blood cells 
were layered onto plastic dishes and allowed to adhere at 37°C for 90 minutes to 
allow the suspended cells to adhere. At the end of the incubation period, the non-
adherent cells were carefully discarded and the adherent monocytes were carefully 
removed and suspended in culture media. The monocytes were about 95% pure 
based on positive staining for CD14 marker.
2.2 Western blotting detection of proteins and phosphoproteins
Sixty million (6 × 106) U937 leukemia cells or monocytes were untreated 
(control) or treated with IL-21 (50 or 100 ng/ml) in a time course (2, 5, 15, 
30, 60 minutes) experiments [48, 49]. At the end of the time course, the cells 
washed 2× with PBS and collected as pellet by centrifugation at 1800 rpm for 
3 minutes. The cell pellets were washed two times with cold PBS and lysed in 500 
μl of lysis buffer A (containing protease inhibitors, 0.5% Triton X-100, 50 mM 
NaF and 2 mM Vanadate) as described in [7]. Total cell lysate protein concentra-
tion was determined by Coomassie Blue Protein Assay Kit (Pierce, IL). Equal 
amount of lysate proteins (120 μg per sample) was resolved by 12% polyacryl-
amide gel electrophoresis followed by transfer of the proteins to membrane 
and blotted against specific antibodies to total Jak2 or Jak3 or Tyk2 or p-Jak2 
or p-Jak3 or p-Tyk2 as previously described [7]. The immunoblot band intensi-
ties were scanned via spot densitometry analysis for quantitation and scanned 
intensity values from the IL-21 treated samples were compared to the intensity in 
the untreated samples.
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2.3 Detection of IL-21R on U937 Leukemia cells and monocytes
Twenty million cells (20 × 106 cells) untreated or treated with 50 ng/ml of IL-21 
for 24 hours were lysed in lysing buffer and protein the concentration was deter-
mined by Coomassie Blue protein determination assay kit [50]. Exactly, 200 μg/lane 
of total cell lysate was separated by 15% polyacrylamide gel electrophoresis and 
the proteins were subsequently transferred to nitrocellulose membrane. Following 
blocking of the background on the membrane, for detection of IL-21R, the nitrocel-
lulose membranes containing transferred protein bands were incubated with 1:1000 
dilution of IL-21 receptor primary antibody (Novus Biologicals) at 4°C in blocking 
buffer (TBS, 0.1% Tween 20, 5% nonfat dry milk) for 1 hour. Next, the membrane 
was washed 3x in water and incubated in milk blocking buffer containing 1:3000 
dilution of goat anti-rabbit IgG HRP antibody (Amersham, CA) for 1 hour at room 
temperature. This was followed by washing with TBS buffer containing 0.5% 
Tween 20. Finally, the membrane was incubated for 1 minute with enhanced chemi-
luminescence (ECL) solution and exposed to Kodak film and band intensities were 
scanned via spot densitometry analysis.
2.4 Detection of Jak1 activation by Jak1 ELISA
To detect Jak1 by ELISA, 96 well plates were pre-coated with 10 μg/ml poly 
lysine for 30 minutes [51]. U937 cells were seeded at 20 × 103/well in 96 well 
plates and incubated in serum free medium overnight. Subsequently, the cells 
were either untreated or treated with 50 or 100 ng/ml of IL-21 for 2, 15, 30 or 
60 minutes followed by rapid removal of the culture medium by aspiration. The 
cells in the wells were fixed with 100 μl of 8% formaldehyde in PBS for 20 min-
utes at room temperature. After removal of the formaldehyde all the wells were 
washed three times with 200 μl of wash buffer (0.1% Triton X-100 in PBS). After 
washing, 100 μl of quenching buffer (wash buffer with 1% hydrogen peroxide 
and 0.1% azide) was added to each well and incubated for 20 minutes at room 
temperature. Then, the wells were washed two times with wash buffer followed 
by incubation of the wells with 100 μl of antibody blocking buffer for 1 hour at 
room temperature. After removal of the antibody blocking buffer the wells were 
washed with 200 μl wash buffer followed by addition in 40 μl of diluted specific 
p-Jak1 or total Jak1 antibody. The wells were covered with parafilm, and incubated 
overnight at 4°C. The primary antibodies were removed by aspiration, and wells 
were washed three times with wash buffer. Next, 100 μl of diluted secondary 
antibody (goat-anti-rabbit HRP) was added to each well and incubated for 1 hour 
at room temperature with head-to-tail shaking. After the incubation, the second-
ary antibody was removed and wells were washed three times with wash buffer 
and once with PBS. The wells were aspirated to remove all traces of liquid, and 
100 μl of developing solution was added to each well. The wells were incubated 
for 15 minutes at room temperature, while monitoring the color development. 
Thereafter, 100 μl of stop solution was added to each well. Lastly, absorbance was 
read at 450 nm using a microtiter plate reader. Experiments were conducted in 
triplicate.
2.5 STAT/DNA binding assays for detection of STAT activation by IL-21
To determine whetherIL-21 induces activation of STAT proteins, untreated and 
IL-21 treated U937 leukemia cells from time course experiments for specific STAT/
DNA binding assays using the STAT transcription factor assay kits (Active Motif, 
Chemicon) [52, 53]. Following stimulation of cells with IL-21, we used the kit to 
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monitor the activation or repression of several STAT proteins. The experiments 
were performed in triplicate.
2.6 Cell cycle analysis for cell growth
U937 cells (1 × 106) were either untreated or treated with 50 ng/ml of IL-21 for 
24 or 48 hours [54, 55]. The cells were packed by centrifugation at 325 × g for 5 min-
utes, washed with cold PBS and suspended in 200 μl PBS. The cell suspension was 
mixed with 500 μl of ice cold ethanol and incubated on ice for 30 minutes. Next, the 
cells were harvested by centrifugation at 325 × g for 5 minutes and the pellets were 
suspended RNAse solution (containing 1 mg RNAse/ml in 0.2 M sodium phosphate 
buffer, pH 7.0) and 50 μl of propidium iodide (PI) solution (0.5 mg PI/ml in water). 
The samples were incubated at room temperature for 30 minutes. The tubes con-
taining the cell suspensions were wrapped in aluminum foil and stored overnight at 
4°C for equilibration. The cells were subjected to FACScan analysis using Cell Quest 
Pro (Becton Dickinson Immunocytometry system) and ModFitLT (v3.1, Versity 
Software House, Inc) to obtain G0, G1, S, and G2M population. For each analysis 
only single cells were analyzed. The data acquisition was set to collect a minimum 
of 104 cells within the single region established for each specimen using FL2-A vs. 
FL2-W plots. Data was analyzed using FL2-A. After establishing optimum condi-
tions for data analysis, instrument settings were maintained constant throughout 
for all analysis.
2.7 Cell proliferation assays
To determine whether IL-21 stimulates cell proliferation in U937 cells, 6 × 106 
cells were either untreated or stimulated with 100 ng/ml of IL-21 for up to 48 hours 
[56]. The cells were harvested at 24 or 48-hour time point. Aliquots of the harvested 
cells from each time point were diluted into 0.4% trypan blue/PBS solution at a 
ratio of 1:10. The cells were counted in triplicate and the average was recorded as the 
cell number for each sample. To validate the results of the trypan blue cell prolifera-
tion assay we performed MTT assay. Briefly, 6 × 106 cells were untreated or treated 
with 100 ng/ml of IL-21 for 24, 48 or 72 hours in 96 well plates. Next, we added 100 
μl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to each 
of the wells. The plates were incubated at 37°C to permit reduction of the MTT by 
the electrons from the viable cells. Four hours later, the MTT formazan produced 
in wells containing live cells appeared as black, fuzzy crystals at the bottom of the 
wells. Next, we added isopropanol and HCl (100 μl) to each of the wells and mixed 
thoroughly. After 1 hour, the absorbance of stable blue color developed in the upper 
phase of the cell pellets (indicative of cell viability) was measured in a microplate 
reader at 750 nm.
2.8 Caspase9 and Caspase3 activity assays as evidence for apoptosis
To determine whether IL-21 induces apoptosis in human U937 leukemia cells 
and human monocytes, we performed caspase9 and caspases3 enzymatic (colori-
metric) assays in cell lysates from untreated and IL-21 treated cells. Leukemia cells 
(10 × 106) and human monocytes (10 × 106) were pretreated with orthovanade 
(5 mM) for 30 minutes [57–59]. The cells were either untreated or treated with 
100 ng/ml of IL-21 for 24 or 48 hours. The cells were lysed in RIPA buffer, and total 
lysate protein concentration was determined as indicated above. To assess the lysate 
for caspases activities, 20 μg total lysate protein from each sample was added to 
each experimental assay well. For positive caspase activity, we used 20 μg of total 
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cell lysates from U937 or monocytes treated with sodium butyrate, which is a strong 
inducer of apoptosis. Caspase9 and caspases3 activities were measured using spe-
cific assay kits (MBL International, Woburn, MA) using specific substrate (p-LEHD 
conjugate) for caspases9 and caspases3 (DEVD-pNA) respectively. The absorbance 
was read at 405 nm with microplate reader.
2.9 Chemotaxis assay
To determine whether culture medium from IL-21 causes chemotaxis, we placed 
culture media from untreated U937 cells or from U937 leukemia cells treated with 
IL-21 for 24 hours in the lower chamber of the Boden Chamber to serve as chemoat-
tractant [60]. Human monocytes ((2 × 105) suspended in RPMI medium) were placed 
in the upper chamber. After 2-hour incubation in the Boyden Chamber, monocytes in 
both the lower and upper chambers counted as instructed by the kit supplier.
2.10 Luciferase assay
To determine whether IL-21 modulates Stat3 promoter function, we per-
formed STAT3-Reporter gene analysis [61, 62]. STAT3-Reporter HeLa stable cells 
(Panomics, CA.) placed in 96 well plates for overnight incubation. The cells were 
either untreated or stimulated with different concentrations of IL-21 for different 
time points up to 24 hours. In some cases the cells were stimulated with different 
concentration of IL-21 (0.2, 5, 10, 12.5, 50, 75 or 100 μg/ml) for to 8–24 hours. As 
a positive control for the STAT3-Reporter gene activation, we treated some of the 
cells with Oncostatin M (Sigma, St. Louis) separately. At the end of the treatments, 
the medium was aspirated and the cells washed two times with PBS. The cells from 
each well were lysed in 100 μl lysing buffer and equal amount of protein in 20 μl 
of the lysate were added to 100 μl of Luciferase Assay Reagent (Promega) and 
the luciferin expression (as indicated by light production) was measured with a 
TD-20/20 luminometer.
3. Results
3.1  Effects of IL-21 on cell proliferation and apoptosis in both human leukemia 
cells and human monocytes
To determine whether IL-21 stimulates cell proliferation in myeloid monocytic 
leukemia cells, we performed proliferation assays on untreated and IL-21 treated 
leukemia cells. As shown in Figure 1a, IL-21 does not stimulate cell proliferation in 
human U937 myeloid monocytic leukemia. These cells express IL-21R. Therefore, 
it was surprising that IL-21 did not promote proliferation as indicated by the 
outcomes of both the trypan blue and MTT assays in cells treated with IL-21 for 
up to 48-hours. Furthermore, our results from cell cycle analysis (Figure 1b) show 
that IL-21 does not promote cell cycle progression during a 48-hour treatment. 
In contrast, IL-21 enhances accumulation of the leukemia cells at G0/G1 phase 
(Figure 1c), suggesting IL-21-induces apoptosis in the leukemia cells. This obser-
vation was validated by the results from specific caspase9 (Figure 2a and b) and 
caspases3 enzymatic assays (Table 1). As can be seen, IL-21stimulates several fold 
activation of both caspases9 and caspases3 activities in the IL-21 treated U937 cells. 
IL-21 produced far less apoptotic effect in monocytes as compared to the control 
(untreated) cells. The ability of IL-21 to stimulate apoptosis shown here is similar to 
an earlier reportin B cells [17].
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3.2  Effects of IL-21 on cytokine and chemokine expression and ERK1/2 activity 
in human leukemia cells and monocytes
In our earlier reports [7, 46] we should that in both U937 leukemia cells and 
monocytes, IL-21 promoted time-dependent differential expression of several cyto-
kines in the order of induction: IL7 > IL-15 > IL-2, IL-1, IFN-γ, TGFβ > GM-CSF and 
chemokines in the order: IL-8 > RANTES, IP-10 > MIP-1a > Eotaxin. Similar results 
were found in monocytes although to different extent. Furthermore, IL-21 triggers 
rapid phosphorylation of ERK-1/2 between 2 and 60 minutes in both leukemia cells 
and monocytes. IL-21-induced ERK1/2 phosphorylation is associated with ERK-
1/2 enzymatic activation. The stimulatory effect of IL-21 on ERK-1/2 activation is 
significantly blocked by a neutralizing antibody against the IL-21R or impartially 
inhibited by the MEK inhibitor U0126 [7]. These results show that IL-21-induced 
interleukin and chemokine expression is partially mediated by ERK-1/2-dependent 
pathway.
3.3 IL-21 utilizes Jak-STAT signaling pathway
Next, we investigated whether IL-21 activates specific members of the Jak/
Stat signaling pathway. Cell lysates from untreated cells or IL-21 stimulated cells 
were analyzed by Western Blot analysis using monoclonal antibody against specific 
members of the Jak/Stat signaling pathway. In some cases, we performed ELISA 
assay using specific ELISA assay kit (Ray Biotech Life, Peachtree Corner, Georgia, 
U.S.A) for specific members of the Jak/Stat signaling pathway [48, 49, 51, 63]. Our 
results (Figure 3) indicate IL-21 causes differential activation of the Jak kinases. 
Notably, Jak1 and Jak2 are rapidly activated in response to IL-21 stimulation; maxi-
mum stimulation occurring within 2–5 minutes. Even though Jak3 and Tyk2 are also 
activated in response to IL-21, the effect is delayed with maximum stimulation by 
IL-21 occurring at between 15 and 60 minutes. Because IL-21 stimulates significant 
activation of the Jak kinases, we examined whether specific members of the Stat 
family are also activated downstream of the Jak kinases. As shown (Figure 4), IL-21 
differentially activates specific members of the STAT family. The order of activation 
was STAT2 > STAT4 > STAT6 > STAT3>. Clearly, IL-2 does not activate STAT1 and 
STAT5. In order to determine whether Jak2 and or Jak3 is responsible for activat-
ing Stat3 and Stat4, we examined the effect of Jak2 inhibitor and Jak3 inhibitor on 
STAT3 and STAT4 activation. Our results (Figure 5) show that in the presence of the 
Figure 1. 
(a and b) Effects of Il-21 on U937 leukemia cell growth.
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Jak2inhibitor, there is significant decline in both STAT3 activation. Clearly, our results 
show that both Jak2 and Jak3 are responsible for STAT3 activation [63]. In contrast, 
the Jak2 inhibitor and Jak3 inhibitor were only slightly effective in inhibiting STAT4 
Figure 2. 
(a) Effect of IL-21 on cell cycle progression. (b) IL-21-induced apoptosis in U937 leukemia cells. Asterisk (*) 
indicates significant difference between IL-21 treatment cells and untreated cells. (c) IL-21-induced apoptosis in 
monocytes. Asterisk (*) indicate significant difference between IL-21 treatment cells and untreated cells.
Experimental condition U937 cells Caspase3 Monocytes Caspase3
(fold activation) (fold activation)
Untreated 1 1
Cells + IL-21 (24 hours) 5.3 2.0
Cells + IL-21 (48 hours) 8.2 2.5
IL-21-Induced apoptosis in U937 cells and human monocytes. Leukemia cells (1 × 106) Or monocytes (1 × 106) were 
untreated (UT) or treated with 100 ng/ml of IL-21 for 24 or 48 hours and cell lysate from each experiment was 
assayed for caspase3 activity. Data represents an average of two experiments.
Table 1. 
IL-21-induced apoptosis in U937 leukemia cells and monocytes.
Cytokines
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activation. Hence, our results suggest Jak2 and Jak3may be involved in activating 
STAT3 [63]. These observations led us to conclude that, Jak2, Jak3 and STAT3 may be 
relevant for IL-21 induced signaling in leukemia cells and monocytes [63, 64].
3.3.1 Effect of IL-21 on chemotaxis: Role of ERK-1 and Jak/STAT proteins
In our previous report, we showed that IL-21 stimulates differential induction of 
cytokine and chemokine expression [7, 40] and that the effect is partially dependent 
Figure 3. 
(a) Effect of IL-21 on Jak1 activation. (b-d) Time course of IL-21-induced differential activation of Jak2, Jak3 
and Tyk2.
Figure 4. 
IL-21 differentially activates STAT1, STAT2, STAT3, STAT4, STAT5 and STAt6.
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on ERK1/2. Given that some of the chemokines including RANTES, MIP-1α could 
induce chemotaxis, we determined if the ERK-1/2 and Jak/Stat signaling pathways 
contributes to induction of chemotaxis. Therefore, we examined the effect of 
pre-incubation of cells with either ERK1/2 inhibitor or Jak2 inhibitor or with both 
prior to stimulation of the cells with IL-21 and assayed the cells for chemotaxis. The 
results (Table 2) confirmed that both the ERK1/2 and Jak2 contribute significantly 
towards IL-21-induced chemotaxis, suggesting that both pathways also contribute 
to IL-21-induced cytokine and chemokines expression. Thus, IL-21 utilizes both 
the ERK-1/2 MAPK and Jak/Stat signaling mechanisms for transducing its signal 
downstream the IL-21R. Perhaps, applications of anti ERK-1/2 and anti-Jak kinases 
agents could be relevant in blocking unwanted IL-21 effects in leukemia patients.
Figure 5. 
Effect of Jak2 and Jak3 inhibitors on IL-21-induced STAT activation. Asterisk (*) indicates significant 
difference between IL-21 treatment alone and either IL-21 treatment in the presence of Jak2 inhibitor or Jak3 
inhibitor.
Experimental condition Chemotaxis (fold change)
Untreated 1
Cells + IL-21 6.3 ± 0.2
Cells + U0126 + IL-21 3.5 ± 0.3
Cells + AG490 + IL-21 2.5 ± 0.1
Cells + U0126 + AG490 + IL-21 1.3 ± 0.1
Cells + U0126 0.9
Cells + Ag490 0.8
Evidence of involvement of ERK-1/2 and Jak2 in IL-21-induced chemotaxis. U937 leukemia cells were either 
untreated (UT) or treated with 100 ng/ml of IL-21 in the presence of either MEK inhibitor (U0126) or Jak2 
inhibitor (AG490) or with both inhibitors. The effect of the each inhibitor alone was determined. Cells were 
incubated for 8 hours and culture medium from each experiment was placed in the bottom insert to serve as 
chemoattractant to monocytes (2 × 105) placed in the upper cup for Boyden Chamber chemotaxis assay. Data 
represents the mean plus SD from three experiments.
Table 2. 
Evidence of involvement of ERK-1/2 and Jak2 in IL-21-induced chemotaxis.
Cytokines
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3.3.2 Effect of IL-21 on STAT3 promoter function
After showing that IL-21 regulates STAT3 phosphorylation and its DNA 
binding activity, we were curious whether IL-21 is capable of regulating the 
STAT3 promoter function. To address this question, we used a construct con-
taining the STAT3 promoter cloned upstream the Luciferase gene (pSTAT3-Luc) 
in HeLa cells from human cervical cancer epithelial cells. We allowed cells to 
recover overnight and divided them into equal number of cells. The cells were 
either untreated or treated with different concentrations of IL-21 in time course 
experiments up to 24 hours. Luciferase assay was performed to determine the 
reporter gene function [61, 62]. The results in Figure 6 indicate IL-21 induces 
a 2.5-fold increase in Luciferase activity in IL-21 treated cells as compared to 
untreated cells. From these results, we conclude that in addition to posttransla-
tional regulation of STAT3, IL-21 is able to activate STAT3 promoter function. 
In addition, to STAT3 promoter regulation, we also noted that IL-21 regulates 
activation of several transcriptional factors including AP-2, Smad3 and 4, Pax-5, 
C-Myc, MEF-1 and CRE [46] that the effects of IL-21 were partially dependent 
on STAT3 activation since siRNA knockdown of STAT3 led to inhibition of 
IL-21’s effects. By activating these transcriptional factors, IL-21 has broader 
regulatory roles that will likely impact on expression of genes downstream of 
these transcriptional factors with potential implicating consequences on the 
biology of different cell types.
4. Discussions
We have provided strong evidence that IL-21 does not promote proliferation 
in U937 myeloid monocytic leukemia cells. We have made nearly similar observa-
tions in THP-1 and HL-60 leukemia cell lines. However, IL-21 strongly promotes 
apoptosis in leukemia cells as has been reported for B cells [58]. In contrast, 
monocytes are somehow resistant to the apoptosis inducing effects of IL-21. These 
results are novel and could have interesting clinical implications and applications. 
Activation of caspases9 and caspases3 by IL-21 reported here, could point to 
Figure 6. 
Effect of IL-21 on STAT3 promoter cloned upstream of luciferase gene in STAT3-reporter-stable Hela cells. 
Asterisk (*) indicates significant difference between IL-21 treatment cells and untreated cells.
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involvement of either extrinsic or intrinsic apoptotic pathway or both and warrant 
further investigation. Currently, studies are underway to elucidate the potential 
involvement of mitochondrial in the mechanism of IL-21-induced apoptosis in 
these cells. Based on its ability to induce apoptosis in leukemia cells while sparing 
monocytes, IL-21 could be considered as potential anti-leukemia agent to kill 
myeloid monocytic leukemic cells [58, 59] or in combination with pro-apoptotic 
agents such as butyrate [65]. Likewise, a combination therapy of IL-21 with other 
cytokines such as IL-34, which promotes monocyte-like differentiation in leuke-
mia cells, could be beneficial as anti-leukemia agent [66]. The stimulatory role of 
IL-21 in chemotaxis and invasion of cancer cells could be explored for develop-
ment of anti-IL-21 drugs to combat IL-21-mediated invasive cancers as previously 
suggested [67–69].
In both leukemia cells and monocytes, IL-21 induces differential expression of 
IL-2, IL-7, IL-15, GM-CSF, TGF-β and IFNγ, which are known to regulate diverse 
cell functions. IL-15 is an effective immunotherapy in conjunction with IL-2. TGF-β 
induction by IL-21 is also very important since TGF-β is a regulator of cell growth 
and differentiation in many different cell types. GM-CSF is a promoter of colony 
formation during bone marrow hematopoietic differentiation as well as a stimulator 
of specific cell-mediated cytotoxicity against tumor targets. IFNγ and IL-7 are both 
relevant for regulation of cellular functions [7]. Thus, some of the effects can be 
beneficial in promoting immune defense in organisms in response to infection by 
pathogens.
The chemokines including IL-8, RANTES and MIP-1α, secreted to the micro-
environment by leukemia cells and monocytes in response to IL-21 in leukemia 
could trigger of chemotaxis [7] as well as mediate cell–cell communication [70]. 
The inflammatory and pro-inflammatory cytokines and chemokines produced in 
response to IL-21 could enhance anti-body secretion and inflammatory responses 
[71, 72], as well as promote inflammatory diseases including arthritis and SLE 
[71–74]. Many of the cytokines induced by IL-21 in these cells could be relevant 
for immunotherapy. In effect, IL-21 could emerge as an effective adjunct immuno-
therapy for many types of cancer via T-cell activation, thus leading to increasing 
cytotoxic effects of NK cells [29]. However, we should not overlook the possibility 
that some of the cytokines and chemokines induced by IL-21 could alter the tumor 
microenvironment, enhance NK cell antitumor activity against MHC Class-I-
deficient tumors, enhance protection against enteric microbial infections, mediate 
radiation-improved IL-21 cancer therapy, promote major oncological applications 
and triggering detrimental side effects including inflammation in cancer patients 
and Crohn’s disease [74–80].
Our study was first to provide evidence that activation of the Raf-MEK-MAPK 
pathway by IL-21 is relevant for some of the biological effects of IL-21 in leukemia 
cells and monocytes [7]. As shown, IL-21 induces rapid activation of ERK1/2, an 
effect, which can either be blocked by a neutralizing antibody against the IL-21R or 
by the MEK inhibitor U0126. Furthermore, our study outcomes suggest that inhibi-
tion of ERK-1/2 leads to significant reduction of IL-21-induced cytokine and chemo-
kine expression in leukemia cells and monocytes. However, inhibition of ERK-1/2 
by the MEK inhibitor U0126 only partially abrogated IL-21-induced cytokine and 
chemokine expression, suggesting involvement of signaling pathway (s) independent 
of Raf-MEK-ERK-1/2.
The Jak/STAT signaling pathway plays major roles in the mechanisms of regu-
lation of cellular functions. Therefore, we examined whether specific members 
of this pathway are activated by IL-21 in leukemia cells. Our results show that 
IL-21 activates Jak2, Jak 3 and Tyk2, which are involved in activating several 
STAT proteins including STAT2, STAT3, STAT4 and STAT6 in both U937 leukemia 
Cytokines
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cells and human monocytes. Using pharmacological inhibitors specific to either 
Jak2 or Jak3, we found that Jak2 and Jak3 play critical roles in mediating phos-
phorylation and activation of STAT3. Furthermore, the induction of chemotaxis 
by IL-21 is dependent on activation of both ERK-1/2 and Jak2. Our study also 
revealed that IL-21 activates Jak1 and Tyk2 as well as STAT1, STAT2 and STAT4 
similar to earlier reports [71–75]. Taken together, both the Raf-MEM-ERK1/2 and 
Jak/STAT signaling pathways mediate IL-21-induced cytokine and chemokine 
expression in leukemia cells and monocytes. However, we are yet to elucidate 
the roles of STAT1, STAT2 and STAT4 in the biological effects of IL-21 in leuke-
mia cells and monocytes. It remains possible that some of these STAT proteins 
activated by IL-21 in these cells will have opposing roles as reported in CD+ T 
cells [75].
The involvement of both the Raf-MEK-ERK and Jak/Stat signaling pathways 
in mediating signaling from the IL-21R and receptors of IL-2 and IL-15 is well 
documented [76, 77]. However, our results were among the first to clearly implicate 
both of these two signaling pathways in the mechanism by which IL-21 induces 
expression of cytokine and chemokines in leukemia cells and normal monocytes. 
These observations are interesting in view of the fact that both of these two 
signaling pathways support cell survival and proliferation and yet IL-21 fails to 
promote proliferation in the leukemia cells. Additionally, we have shown that IL-21 
activates the STAT3 promoter suggesting that genes including anti-apoptotic and 
pro-apoptotic genes with STAT3 promoter can be regulated by IL-21 in leukemia 
cells. In addition, IL-21 regulates other transcriptional factors including Smad3/4, 
AP-2, Pax-5, C-myc, MEF-1 and CRE via partial STAT3-dependent mechanism. 
As illustrated by our model (Figure 7) upon binding to its receptor, IL-21 activates 
multiple signaling pathways, which are critical to the observed IL-21’s biological 
effects in leukemia cells and monocytes.
The potential for IL-21 to play a role in immunotherapy including its role in 
cancer therapy is extensively documented [77–82]. Our work points to the need to 
expand research on IL-21 in different leukemia cells with the anticipation that the 
outcomes will provide new ideas for exploring IL-21 in combination therapy for 
Figure 7. 
Proposed signaling model for IL-21 in leukemia cells and monocytes.
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leukemia. Lastly, we propose that targeting the major pathways modulated by IL-21 
could lead to new opportunities for treating leukemia.
5. Conclusion
Our findings indicate that both U937 leukemia cells and human monocytes 
express IL-21R. In these cells, IL-21 induces differential expression of various 
cytokines and chemokines and promotes chemotaxis. These biological effects of 
IL-21 could be associated with either negative clinical implications or positive 
clinical applications in leukemia patients. The Raf-MEM-ERK1/2 pathway and 
the Jak-STAT pathway play critical roles in induction of cytokine and chemo-
kine expression by IL-21. Activation of the Jak2 and STAT3 is germane to these 
effects. Furthermore, IL-21 activates apoptosis in U937 leukemia cells with little 
or no apoptotic effect on human monocytes. The inability of IL-21 to induce 
apoptosis in human monocytes while inducing significant apoptosis in leukemia 
cells could form the basis for future application of IL-21 as a potential therapeu-
tic factor for various types of leukemia. Lastly, the ability of IL-21 to regulate 
the STAT3 promoter function suggests that genes including pro-apoptotic or 
anti-apoptotic genes with STAT3 promoter sequences are likely to be modulated 
by IL-21.
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